Richard Saynor (Sandoz (division of Novartis))

Saynor, Richard (Novartis 2019Q1– CEO of Sandoz)

	Organisation	Sandoz (division of Novartis)
	Group	Novartis (Group)
	Product	DRUGS, GENERICS
	Source	Novartis AG. (4/24/19). "Press Release: Novartis Starts 2019 with Strong Sales and Double Digit Core Operating Income Growth, Mayzent Launch and Alcon Spin-off, Profit Guidance Upgraded". Basel.

Record changed: 2023-10-04

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Richard Saynor

[1] Sandoz Group AG. (10/4/23). "Press Release: Sandoz Enters New Era as Standalone Global Leader and European Champion in Generic and Biosimilar Medicines". Basel....
[2] Novartis AG. (9/11/23). "Press Release: Sandoz Announces Exclusive Deal to Commercialize Biosimilar Ustekinumab". Basel....
[3] Novartis AG. (1/24/23). "Press Release: Sandoz Announces Agreement to Acquire Leading Antifungal Agent Mycamine from Astellas, Reinforcing Hospital Offering and Leading Anti-infectives Portfolio". Basel....
[4] Novartis AG. (2/11/21). "Press Release: Sandoz Announces Agreement to Acquire GSK’s Cephalosporin Antibiotics Business, Reinforcing Its Leading Global Position in Antibiotics". Basel....
[5] Novartis AG. (4/24/19). "Press Release: Novartis Starts 2019 with Strong Sales and Double Digit Core Operating Income Growth, Mayzent Launch and Alcon Spin-off, Profit Guidance Upgraded". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]